

Index

a

- α interaction domain 71
- α_1 subunit 69 ff.
- α_2 - δ subunit 57, 69 ff.
- α -Dendrotoxin (DTX) 217
 - selectivity 219
- A-278637 344 ff.
- A-411873 323
- acetylcholine receptor deficiency 408
- AChR 410
- action potential 44, 55
- adipocytes 244 ff.
 - brown fat 244
 - glucose transporter 244
 - white fat 244
- afterhyperpolarization 314
- Agelopsis aperta* 131
- alkaloid 319, 328
- ALMOND modul 432 ff.
- Alzheimer's disease 317
- ambasilide 278
- amiloride-sensitive epithelial sodium channel 397
- 4-aminopyridine 222
- amiodarone 29, 278
- amitriptyline, Na_v blocking activity 186
- amlodipine 89 ff.
- amygdala-kindling model 357 ff., 361
- anandamide 91
- ancillary calcium channel subunits 69 ff., 77
- Andersen-Tawil syndrome 383
- anesthetics 87
- anosmia 251
- antiarrhythmic drugs 9, 278
- anticonvulsant
 - amygdala-kindling 357 ff.
 - 6 Hz model 361
 - maximal electroshock 357 ff.
 - pentylenetetrazol 357 ff.
 - picrotoxin 357
- antiepileptic drugs, receptor sites 9
- antiepileptics 87
- anxiety 369
 - canopy test 369 ff.
- apamin 242, 244, 326 f.
- apoptosis 237
 - Fas receptor 237
 - mitochondria 237
- aryloxindole 321
- arylpyrrole 323
- asthma 324
- ATP-sensitive potassium channel K_{ATP} 335, 385
- atrial effective refractory period (AERP) 291
- atrial fibrillation 276
- atrial vulnerability 291
- autism 396
- autoantibodies 238
- autoimmune diseases 247 ff.
- autosomal dominant
 - juvenile myoclonic epilepsy 412
 - nocturnal frontal lobe epilepsy 410
- auxiliary subunit in
 - $\text{K}_v\beta$ 11
 - KChIp1-4 11
 - minK 11
- auxiliary subunits
 - $\text{Ca}_v\alpha 2$ 10
 - $\text{Ca}_v\beta$ 10
 - $\text{Ca}_v\delta$ 10
 - $\text{Ca}_v\gamma$ 10
 - $\text{Na}_v\beta 1$ 9
 - of K^+ channels 198
- AVE0118 287, 289
- azaindole 323
- azimilide 278

b

- β cell rest 341
- β subunits 69
- β-cell overwork 341
- β-tryptase inhibitors 440
- β1-integrin 236
- B cell 215, 234, 237, 247
 - memory B cell 237 ff.
 - proliferation 237
 - T_{CM} 247 ff.
 - T_{EM} 247 ff.
- Ba²⁺ 86
- Ball, channel expression 238
- barnidipine 89 ff.
- Bartter syndrome 406
 - type 2 383
 - type 4 407
- barttin 406
- Becker's syndrome 403
- benidipine 89 ff.
- benign familial neonatal
 - convulsions 388
 - infantile seizures 396
- benzamides 235
 - binding site 227
 - Hill coefficient 227
 - PAC 227
 - SAR 227
 - selectivity 227
 - trans-N-propyl-carbamoyloxy PAC 227
- benzimidazolinone 326, 329
- benzimidazolone 320
- benzooxazolone 326, 329
- benzothiazepine class 103
- bepidil 278
- binding 56
- biophysical properties 159
 - activation 160
 - recovery from inactivation 160
 - state-dependent sodium channel blocker 161
 - steady-state inactivation 160
 - use-dependent 162
- bladder 245
 - hyperactivity 315
 - K⁺ channel expression 245
 - overactivity 323, 326
- blockers
 - aliphatic monoamines 138 ff.
 - ω-agatoxin-IIIa 128
 - conclusions 140 ff.
 - ω-conotoxin-GVIA 127
 - ω-conotoxin MVIIC 128
 - dialkyl-dipeptidylamines 132
 - dihydropyridines 139 ff.
 - ethanol 140 ff.
 - huwentoxin-I 127
 - imidazolines 139 ff.
 - non-specific N 128
 - piperazines 136 ff.
 - small organic molecule 132 ff.
 - substituted L-amino acids 132
 - substituted piperidines 136 ff.
 - unsaturated hydrocarbons 138 ff.
 - venom of the spiders 128
 - volatile anaesthetics 139
- BMS 191011 322
- BMS-180448 338
- BMS-189269 320
- BMS-191095 338
- BMS-204352 312, 321
- Boltzmann curve 23
- Boltzmann function 26
- bone resorption 250
- borderline SMEI 395
- Brugada syndrome 394 f.
- bupivacaine 29, 171
 - structure 172

c

- CACNA1A 401 f.
- CACNA1C 400
- CACNA1F 401
- CACNA1H 403
- CACNA1S 399
- CACNB4 402
- calcium activators 100
- calcium channel 9, 65, 382, 399
 - L-type 27
 - N-type 122
 - T-type 23, 27, 42, 84
- calcium channel blockers 100
 - abscisic acid 108
 - amlodipine 102
 - benzacocine CGP 108
 - benzothiazepine 103
 - BMY 20064 104
 - calciseptine 115
 - calcludine 115
 - clotrimazole 114
 - 1,4-dihydropyridine 103
 - diltiazem 101 ff.
 - dodecanol 114
 - dodecylamine 114
 - felodipine 102
 - FPL 64176 108

- gene delivery 118
- HOE 166 104
- isradipine 102
- L 652,469 104
- L-calchin 115
- MCI 176 104
- McN-5691 104
- McN-6186 104
- MDL 12,330 104
- menthol 104, 114
- mibefradil 115
- nicardipine 102
- nifedipine 101, 103
- nimodipine 102
- peptide toxins 115
- phenylalkylamine 103
- praziquantel 117
- (-) S bay k 8644 108
- (+) S 202-791 108
- SR 33557 104
- structure-activity relationships 102
- tetrandine 104
- tinuvin 770 114
- verapamil 101, 103
- vitamin D 115
- WAY 141520 117
- calcium channel knockout 76
- calcium currents
 - L-type 10, 65, 101
 - N-type 10, 65, 123
 - P/Q-type 10, 65
 - R-type 10, 65
 - T-type 10, 65, 84
- calcium ions 65
- calcium signaling 235
- calcium-activated K⁺ channel 196, 199 ff., 310
- calcium-dependent inactivation 70
- candidate gene approach 381
- canopy test 369
- carbamazepine 21, 32
 - derivatives 173
 - metabolism 173
 - neuropathic pain 173
 - structure 173
- carrageenan model 359
- Cav1.1 399
- Cav1.2 400
 - L-type 31
- Cav1.4 401
- Cav2.1 401
- Cav2.2 32, 403
- CC2-DMPE 52
- CCR7 233 f., 250
- T_{EM} 247
- CD4⁺ 233
- CD8⁺ 233
- CD27 234, 237
- CD45RA 233 f.
 - T_{EM} 247
- CDP-840 434, 436
- central memory (T_{CM}) 232
- cerebellar ataxia 314
- cetiedil 324
- CFTR chloride channel 407
- CGS-7181 323
- CGS-7184 323
- chalcone-16 230
 - pharmacological properties 225
 - selectivity 220
- channelopathy 381 ff., 412
- charybdotoxin (ChTX) 57, 216 f., 318
 - selectivity 219
 - sequence 218
- childhood absence epilepsy 396
- chloride channel 382, 403
- chloroquine 430
- chlorzoxazone 326
- CHO cells 429
- chromanol 293B 278
- chronic constriction injury model 357
- chronic graft versus host disease (GvHD)
 - 215, 237, 247
 - pathogenesis 250
 - therapies 250
- ChTX 233, 235, 242, 245 f.
- cisapride 430, 434
- Cl_{Ca} 50
- ClC-1 403
- ClC-2 404
- ClC-5 405
- ClC-7 406 f.
- ClC-Ka and ClC-Kb channels 406 f.
- CLCN-K 406
- CLCN1 403
- CLCN2 404
- CLCN5 405
- CLCN7 406
- Clofilium 278
- ClogP 431
- clotrimazole 242, 319, 324
- CMR 431
- CNG Channels 390 f.
- CoMFA 434
- CoMSiA 434
- cone snail toxins
 - disulfide pattern 221

- four disulfide bonds 221
 - congenital myasthenic syndromes 408
 - congenital stationary night blindness
 - type 2 401
 - Conus catus* 127
 - Conus geographus* 130
 - Conus magus* 130
 - ω -conotoxin-MVIIA 126
 - conus striatus* 130
 - ω -conotoxin GVIA 66, 126 f.
 - ω -conotoxin MVIIA 68
 - CoroNa Green 58
 - correolide 215, 217, 224, 235, 245
 - C18-analog 227
 - binding-site 226
 - pharmacological properties 225
 - selectivity 220, 227
 - *spachea correa* 226
 - structure 223
 - T cell proliferation 227
 - CP-339818 224 f.
 - selectivity 220, 225
 - structure 223
 - CRAC 234, 236
 - crobenetine
 - analgesic properties 177
 - regiochemistry 176
 - structure 177
 - treatment of ischemic stroke 177
 - cromakalim
 - bladder inhibitory effects 344
 - cardioprotective effects 338
 - clinical effects on bladder 343
 - in vitro (pig bladder strip) 347
 - pharmacological tools 335
 - cyclic nucleotide-gated channel 390
 - CYP2C9 inhibition 440
 - cystic fibrosis 316, 407
- d**
- DC-EBIO 326
 - de novo* design 299
 - dehydrosoyasaponin-1 324
 - delayed type hypersensitivity (DTH) 236
 - deltamethrin 55
 - dendrotoxin 57
 - Dent's disease 405
 - DHS-1 324
 - Di-ANEPPS 51, 55
 - diabetes 340
 - dialkyl-dipeptidylamines 132 ff.
 - diazoxide
 - antihypertensive 336
 - cardioprotective effects 338
 - β cell function 341
 - hypoglycemia 336
 - insulinomas 340
 - nesidioblastosis 340
 - pharmacological tools 335
 - polycystic ovary syndrome 340
 - side effects 341
 - DiBAC 51 f.
 - dichlorophenylpyrazolopyrimidines 228
 - diclofenac 375 ff.
 - dihydropyridine 21, 325
 - 1,4-dihydropyrimidine 709
 - 1,4-dihydropyridine class 103
 - activators 113
 - amlodipine 106, 108
 - benidipine 106
 - clinically available 110
 - clinidipine 106
 - conformational requirements 109
 - felodipine 106
 - isradipine 106
 - lacidipine 106
 - lercanidipine 106
 - manidipine 106
 - nicardipine 106
 - nifedipine 106
 - nilvadipine 106
 - nimodipine 106
 - nisoldipine 106
 - nitrendipine 106
 - NO-releasing activities 113
 - privileged structure 106, 114
 - QSAR 109
 - state-dependence 110
 - state-dependent interactions 111 f.
 - stereoselectivity 107
 - structure–activity relationships 107, 110
 - vascular cardiac selectivity 111
 - dihydropyridine K_{ATP} blocker 345
 - dihydropyridine K_{ATP} openers 345
 - dihydropyridines 66, 89, 139
 - dihydroquinolones
 - CP-339818 224
 - 125 I-ChTX-displacement 224
 - mechanism of channel block 224
 - patch-clamp 224
 - 86 Rb-efflux 224
 - WIN-17317-3 224
 - diisopyramide 28
 - diltiazem 21, 223, 278
 - diphenylurea 320
 - disease association 162

- channelopathies 162
 - febrile seizures plus (GEFS+) type 2 163
 - GEFS+ type I 163
 - hyperkalemic periodic paralysis 162
 - long Q-T syndrome type 3 163
 - myotonias 162
 - paramyotonia congenita 163
 - potassium aggravated myotonia 163
 - primary erythralgia 163
 - disease indications 246 ff.
 - distribution of VGCCs 66
 - dofetilide 57
 - dopamine 328
 - drain plug model 434
 - dronedaron 278
 - drug acquired LQTS 447
 - drug binding sites 207
 - d-sotalol 278
 - ducky mouse 77
- e**
- EAE 247
 - 1-EBIO 317, 326, 329
 - effector memory (T_{EM}) 232
 - efonidipine 89 ff.
 - electrical signals 7
 - ENaC 397
 - ENaC channel 397
 - encainide 28
 - epilepsy 77, 355 ff.
 - epilepsy with grand mal seizures
 - on awakening 404
 - episodic ataxia 76
 - type 1 386
 - type 2 401
 - epithelia 245
 - K^+ channel expression 245
 - epitope spreading 252
 - erectile dysfunction 322
 - erg-2 242
 - erythromycin 57
 - ethanol 140
 - ethosuximide 87 ff.
 - 1-ethyl-2-benzimidazolinone 317
- f**
- familial hemiplegic migraine 401
 - Fas receptor 237
 - apoptosis 237
 - fast channel syndrome 410
 - febrile seizures associated with
 - afebrile seizures 396
 - felodipine 89
 - Filistata hibernalis* 128, 131
 - flecainide 28, 278
 - FLIPR 58
 - FLIPR[®] 33
 - flunarizine 88 ff.
 - fluorescence 56 f.
 - fluorescence resonance energy transfer 429
 - flupirtine (Katadolon[®]) 355 ff.
 - formalin model 359 ff.
 - frequency dependence 45
 - FRET 52 f., 55
- g**
- $G\beta\gamma$ 74
 - GABA_A 412
 - receptors 412
 - gabapentin 57
 - gain of function 382 ff., 385, 388, 390 f.,
 - 393 ff., 403, 410
 - gate 22
 - gating 208
 - state 19
 - gene 214
 - generalized febrile epilepsy plus 395, 397
 - genetic and acquired channelopathies 381
 - GIRK 50
 - GLRA 410
 - GLRB 410
 - glucose transporter 244
 - glyburide
 - anti-arrhythmic activity 339
 - antidiabetic agent 336
 - insulin-releasing properties 340
 - pharmacological tools 335
 - glycine receptors 410
 - goats model of AF 291
 - Grammostola spatulata* 128, 130
 - Grave's disease 238
 - green fluorescent protein 53
 - GRIND-based model 432
 - [¹⁴C]-guanidium, ion flux 58
 - γ subunits 69
- h**
- haloperidol 88 ff.
 - Hashimoto's thyroiditis 238
 - HCN Channels 391
 - hearing 314
 - heart 246
 - K^+ channel expression 246
 - HEK cells 429
 - hERG 38, 55, 57, 59, 242, 389 f.
 - channel 207, 428

- channel mutations 430
 - h-erg potassium channel 389, 444 ff.
 - antihistamines terfenadine 449, 454
 - antipsychotic drugs 450
 - arsenic trioxide 454
 - astemizole 449
 - blockers, not LQT 454
 - cisapride 450
 - clarythromycin 453
 - clomiphene 454
 - erythromycin 453
 - fluoroquinolone antibacterials 450
 - grepafloxacin 450
 - haloperidol 450
 - interactions 449
 - macrolide antibiotics 453
 - sparfloxacin 450
 - thioridazine 450
 - trafficking effects 454
 - verapamil 454
 - high-throughput screening 33
 - high voltage activated (HVA) currents 66
 - hinge 14
 - HIV-related neuropathy 243
 - HMR-1556 278
 - HMR1883 340
 - Hodgkin–Huxley 20
 - model 30
 - homology model 300
 - homopiperidine 324
 - HQSAR, hologram QSAR 431
 - hyperkplexia 411
 - hyperinsulinaemic hypoglycaemia
 - of infancy 385
 - hyperinsulinemia 340 f.
 - hyperkalaemic periodic paralysis 76, 393, 399
 - hyperpolarization-activated cyclic
 - nucleotide gated channels 391
 - hypomagnesaemia with secondary
 - hypocalcaemia 392
 - hypoxia 237
 - 6 Hz “psychomotor” test 361
- i**
- I_{Kr} 389
 - iberiotoxin 319
 - ICA-17043 324
 - ICH 444 ff.
 - E14 446
 - guidelines 445 ff.
 - S7A 446 ff.
 - S7B 446
 - Ig-fold 9
 - IgD 234, 237
 - IK_{ACh} 50
 - IK_R 42
 - IK_S 42
 - IK_{ur} 276
 - IL2 production 225
 - imidazolines 139
 - immunological synapse 235 ff.
 - imodipine 89
 - inactivation 22
 - incontinence 323
 - indications 186
 - indole urea 323
 - infantile malignant osteopetrosis 406
 - infantile spasms 395
 - inflammatory pain 359
 - inherited disorders 381 ff.
 - insomnia 412
 - integrated risk assessment 444 ff., 455 ff.
 - intermediate-conductance 310
 - intractable childhood epilepsy 395
 - inward rectifiers 200 ff., 383
 - inward-rectifying K^+ channels 12, 196
 - ion flux 57 f.
 - ischemia 320
 - ischemic preconditioning 337
 - IsK 386
 - isoflurane 87 ff.
 - isolated cardiac conduction defect 394 f.
 - isridapine 89
- j**
- Jervell and Lange-Nielson syndrome 387
 - juvenile absence epilepsy 404
 - juvenile myoclonic epilepsy 402, 404
- k**
- K_{ATP} drug-related patent applications 349
 - K_{ATP} openers for alopecia 348
 - K_{ATP} partial agonist 346
 - K_{ATP} radioligand 345
 - kaliotoxin 215 ff., 246, 250
 - selectivity 219
 - sequence 218
 - Katadolon® 355
 - $K_{Ca1.1}$ 312, 318
 - $K_{Ca2.1}$ 327
 - $K_{Ca2.2}$ 327
 - $K_{Ca2.3}$ 327
 - $K_{Ca3.1}$ 231, 238, 245 f., 315, 324
 - expression 233 ff., 234
 - $K_v\beta 2$ 235
 - K^+ channel 11, 382, 385

- auxiliary subunits 201
- blockers 214
- classification 194
- crystal structure 201
- diseases 194
- herg 29
- toxins 210
- KCMA3 312
- KCNA1 386
- KCNE1 386 f.
- KCNE2 389
- KCNH2 389
- KCNJ1 383
- KCNJ2 383
- KCNJ11 385
- KCNMA1 312
- KCNMB1 314
- KCNN1 316
- KCNN2 316
- KCNN3 316
- KCNN4 315
- KCNQ channels 355 ff.
- KCNQ1 386 f.
- KCNQ2 388
- KCNQ3 388
- KCNQ4 388
- KCNT2 312
- KcsA channel 428, 430
- KDR kinase inhibitors 437
- khellinones 223
 - chalcone-16 223, 227, 230
 - Hill coefficients 230
 - dimers 230
 - selectivity 230
- kinetics 45
- Kir1.1 383
- Kir2.1 241, 243, 383
- Kir3 50
- Kir4.1 243
- Kir6.2 385
- KirBac1.1 channel 428
- Kv1.1 232, 385 f.
- Kv1.2 232
- Kv1.3
 - apoptosis 237
 - B-lymphocytes 214
 - expression 233 ff.
 - gene 214
 - hypoxia 237
 - knockout mice 251
 - $K_v\beta 2$ 235
 - macrophage 214
 - microglia 214

- null mice 215
- olfactory bulb 214
- oligodendrocytes 214
- osteoclasts 214
- peptide inhibitors 216
- phosphorylation 235
- physiological role 231 ff.
- platelets 214
- single-channel conductance 231
- Kv1.4 243
- Kv1.5 240, 242 f.
 - channel blocker 275
 - homology modul 275
 - pharmacophore model 275
- Kv1.6 232, 243
- Kv3.1 232
 - null mice 232
- Kv7.2-7.5 355
- Kv11.1 242
- Kv11.2 242
- Kvap channel 428
- KvLQT1 386, 388
- KYS05044 91 ff.

I

- Lambert-Eaton myasthenic syndrome 402
- lamotrigine 32, 175 ff.
 - binding site 170 ff.
 - history 168
 - indications 168
 - pharmacology 171 ff.
 - sodium channel block 171 ff.
 - structure 170 ff.
- large-conductance 310
- laudanosine 328
- lead identification 296
 - pharmacophore-based 299
 - structure-based 299
- lethargic mouse 77
- levosimendan 339, 349
- Liddle's syndrome 397
- lidocaine 27 ff., 31, 175 ff., 181 ff.
 - binding site 171 f.
 - history 168
 - indications 168
 - mechanism of block 169 ff.
 - neuropathic pain 168, 172 ff.
 - postherpetic neuralgia 172 ff.
 - structure 172
- ligand binding 204
- ligand operated channels 382
- ligand-based
 - chemometric models 430

- model 428
 - ligand-gated channels 408
 - local anesthetics, receptor sites 9
 - long QT syndrome (LQTS) 389 f., 444
 - type 1 386
 - loss of function 382 ff., 383, 386 ff., 394 ff., 401, 403, 405 f.
 - low voltage activated (LVA) currents 65
 - L-type 66
 - L-type calcium channel 42, 399
 - blockers 89
 - calcium activators 100
 - calcium antagonists 100
 - calcium channel blockers 100
 - calcium entry blockers 100
 - gabapentin 116
 - pregabalin 116
 - splice variants 112
 - state-dependent interactions 112
 - $\alpha_1\text{-}\beta$ subunit site of interaction 117
 - $\alpha_2\delta$ subunit 116
 - L-type channel 100, 122
 - cinnarizine 101
 - flunarizine 101
 - prenylamine 100
 - verapamil 100
 - LQT7 384
 - lymphocytes 55
- m**
- macrophage 239 ff.
 - KCa1.1 240
 - K^+ channel 239
 - Kir2.1 241
 - Kv1.3 239
 - Kv1.5 240
 - membrane potential 240
 - [^3H]thymidine incorporation 240
 - malignant hyperthermia 399
 - margatoxin 215 ff., 219, 232, 235, 237, 240, 245
 - pharmacological properties 225
 - selectivity 219
 - sequence 218
 - marketed K_{ATP} modulating drugs 336
 - maxikdiol 324
 - maximal electroshock 357
 - MaxiPostTM 321, 362 ff.
 - M currents 355, 388
 - mechanisms of drug block 169
 - use-dependent 170
 - meclofenamic acid 375 ff.
 - membrane potential sensing dyes 51 ff.
 - memory T cells
 - central memory (T_{CM}) 232
 - effector memory (T_{EM}) 232
 - methsuximide 87 ff.
 - 5-methoxypsoralen 229
 - mexiletine 171, 175 ff.
 - analogues 180 ff.
 - structure 172
 - mexilitine 21, 29
 - mibefradil 21, 24 f., 90 ff.
 - mice lacking the Kv1.3 232
 - microglia 241 ff.
 - amoeboid 241 ff.
 - K^+ channel 241 ff.
 - migration 242
 - proliferation 242
 - ramified 241 ff.
 - respiratory burst 242
 - migraine 364 ff.
 - MinK 386 f.
 - minoxidil 338, 348
 - MiRP1 38, 389 f.
 - mitochondrial K_{ATP} (mito- K_{ATP}) channel 335, 337
 - opener 338
 - MK-499 430, 434
 - 5-MOP, Structure 223
 - modulated receptor hypothesis 46
 - modulated receptor model 24, 27
 - monophasic action potentials (MAP) 291
 - MS 232, 237 f., 247
 - Mthk channel 428, 430
 - multiple sclerosis (MS) 215
 - EAE 247
 - MS lesion 247
 - myelin antigen-specific T cells 247
 - therapies 248
 - muscle acetylcholine receptors (AChR) 408
 - mutations 381 ff.
 - myasthenic syndrome 393 f.
 - myocardial ischemia 337
 - myogenic bladder overactivity 343
 - myotonia congenita 403

n

 - Na_v subtypes 169
 - Na_v blockers 187
 - indications 186
 - neurodegenerative disease states 186
 - new structural classes 180
 - $\text{Na}^+\text{-K}^+\text{-ATPase}$ 245
 - natural killer cells 239
 - Nav1.1 395

- Nav1.2 396
 - Nav1.4 393
 - Nav1.5 394
 - neurogenic bladder overactivity 343
 - neuroleptics 88
 - neurological disorders 329
 - neuromuscular transmission 403
 - neuronal AChR 410
 - neuropathic pain 355 ff.
 - neuropeptide Y, Y5-receptor antagonists 436
 - neuroprotection 322, 326
 - NFAT 236
 - Ni²⁺ 86
 - nifedipine 27, 89, 325
 - structure 223
 - night blindness 76
 - nimodipine 89
 - NIP-141 284
 - NIP-142 284
 - nitrendipine 27, 89, 223, 325
 - nitrous oxide 88
 - NMDA receptor 27
 - NN414 341 f.
 - NNC 55-0118 341
 - NO-releasing activities,
 - 1,4-dihydropyridines 113
 - nociception 32, 320
 - non-selective cation channels 382, 390
 - novel K_{ATP} chemotypes 347
 - NS-4 320, 322
 - NS-8 323
 - NS-309 326, 328
 - NS-1608 320
 - NS-1619 320
 - NS-4591 328
 - NS-1619 314
 - N-type 66
 - N-type calcium channel
 - blockers 123 ff.
 - pharmacology 123
 - N-type channel peptide antagonists
 - ω-agatoxin IVA 131
 - ω-conotoxins 130
 - DW13.3 131
 - huwentoxin-I 131
 - *in vitro* 130
 - *in vivo* 130
 - kurtoxin 131
 - ω-phonetoxin IIA 131
 - SNX-325 131
 - N-type channels 403
 - Cav2.2 122 f.
 - ω-conotoxin-GVIA 126
 - GABA_B 123
 - inorganic cations 124
 - peptide blockers 125
 - specific blockers 125
- o**
- obesity 251
 - octanol 87
 - Ohm's law 39
 - olfactory bulb 244
 - super-smeller 244
 - oligodendrocytes 243 ff.
 - differentiation 243
 - K⁺ expression 243
 - precursors 243
 - proliferation 243
 - oocytes 429
 - Ornithoctonus huwena* 131
 - huwentoxin-I 127
 - OSK1 219
 - osteoclasts 245 ff.
 - bone resorption 246
 - K⁺ channel expression 245 ff.
 - membrane potential 246
 - overactive bladder (OAB) 343
 - oxadiazolone 322
- p**
- PAC 224
 - Hill coefficient 227
 - pharmacological properties 225
 - selectivity 220, 227
 - structure 223
 - trans-N-propyl-carbamoyloxy PAC 227
 - pain 32, 76
 - pain (inflammatory),
 - carrageenan assay 358 ff.
 - pain (neuropathic)
 - chronic constriction injury (CCI) 357 ff.
 - spared nerve assay 359 ff.
 - spinal nerve ligation 359 ff.
 - streptozotocin assay 369 ff.
 - pain (persistent), formalin assay 358 ff.
 - pancreatic β-cell K_{ATP} 335
 - PAP-1 217
 - oral availability 229
 - pharmacological properties 225
 - selectivity 220, 229
 - structure 223
 - Parabuthus transvaalicus* 131
 - Paramyotonia congenita* 393
 - patch clamp 39 ff., 59

- assay 429
 - paxilline 240, 319
 - Pb²⁺ 86
 - PBFI 58
 - PDE4 inhibitors 434
 - penfluridol 88 ff.
 - pentylene-tetrazol 357 ff.
 - peptide inhibitors 216 ff.
 - peptide toxins 318, 327
 - peptidomimetic 228
 - Per-Arnt-Sim domain 428
 - pharmacophore model 299
 - 3-dimensional 431
 - phenobarbital 87 ff.
 - phenyl-stilbene A 228
 - structure 223
 - phenylalkylamine class 105
 - phenytoin 20, 27, 32, 87 ff., 175 ff.
 - history 168
 - indications 168
 - neurodegenerative disease states 186
 - neuroprotection 174 ff.
 - structure 174 ff.
 - phoneutria nigriventer* 131
 - venom of the spiders 128
 - phylogenetic analysis 154 ff.
 - evolutionary perspective 156 ff.
 - four-domain family 154 ff.
 - Na channel genes 156 ff.
 - SCN1A 157 ff.
 - SCN2A 157 ff.
 - SCN3A 157 ff.
 - SCN4A 157 ff.
 - SCN5A 157 ff.
 - SCN8A 157 ff.
 - SCN9A 157 ff.
 - SCN10A 157 ff.
 - SCN12A 157 ff.
 - physicochemical models, 2-dimensional 431
 - pig model of AF 291
 - pinacidil 335 f., 341, 347
 - cardioprotective effects 338
 - pimozide 88 ff.
 - piperidines
 - binding site 226
 - Hill coefficient 226
 - patch clamp 226
 - ⁸⁶Rb-efflux 226
 - selectivity 226
 - UK-78282 226
 - pK_a 431
 - PKA kinase anchoring proteins 73
 - planar patch clamp 48 ff.
 - platelets 246
 - K⁺ channel expression 246
 - polymerase chain reaction 381
 - pore 9-10, 12 f.
 - Posicor™ 90
 - positional cloning 381
 - potassium channels; *see K⁺ channel* 11, 382, 385
 - potassium selectivity region 428
 - potassium-aggravated myotonia 393
 - P/Q-type 66
 - pregabalin 57
 - Prialt® (ziconotide) 32
 - primary and tertiary structure 152
 - IFM motif 154
 - membrane topology 152
 - P-loop 152
 - privileged structures 103, 296
 - progesterone 230
 - propafenone 278
 - propofol 87 ff.
 - prostate cancer 326
 - protein crystal structure 59
 - protein kinase C 73
 - protein superfamily 7
 - provisional safety margins,
 - 30-fold margin 456
 - pseudohypoaldosteronism type 1 397
 - psora-4 217, 224, 235
 - Hill coefficient 229
 - PAP-1 229
 - pharmacological properties 225
 - selectivity 220, 229
 - structure 223
 - psoralens 224
 - H37 229
 - 5-methoxypsoralen 229
 - PAP-1 229
 - pharmacophore 229
 - psora-4 229
 - ruta graveolens 229
 - SARs 229
 - psoriasis 215, 247
 - autoantigens 249
 - pathogenesis 249
 - therapies 250
 - purkinje fiber 59
- q**
- QT interval 384 f., 387 f., 390, 394 f.
 - QT-prolongion 434
 - quantitative structure activity relationship (QSAR) 431

- quinidine 28, 278
 quinine 223
 quinolinium 328
 quinolinone 322
- r**
- RA 247
 ralfinamide 177 ff.
 – pain models 178 ff.
 – pharmacokinetics 178 ff.
 – SAR (structure–activity relationship) 178 ff.
 – structure 177
 – treatment of neuropathic pain 177 ff.
⁸⁶Rb, ion flux 58
 reduced repolarization reserve 457
 remodeled atria 291
 resc scaffolding 298
 restenosis 316
 retigabine 355 ff.
 retina 245
 – K⁺ channel expression 245
 retinitis pigmentosa 390
 rheumatoid arthritis (RA) 215, 237
 – pathogenesis 249
 – synovial fluid 249
 right bundle branch block 395
 riluzole 326, 329
 R-type 66
 rubidium efflux assay 428 f.
Ruta graveolens 229
 ryanodine receptor 399
- s**
- S20951 289
 safety pharmacology 444
 safinamide
 – epilepsy 177 ff.
 – Parkinson's disease 177 ff.
 – restless legs syndrome 177 ff.
 – structure 177
 SAR 137 f.
 sarcolemmal cardiac K_{ATP} 335
 – blocker 339
 SBF1 58
 SCN1A 395
 SCN2A 396
 SCN4A 393
 SCN5A 394 f.
 SCNB1 397
 scorpion toxins
 – contacts with channel 216
 – disulfids pattern 216
 – sequence 218
 – structure 216
 screen sequence 38
 SCREENIT 457
 sea anemone toxins 221
 – disulfide pattern 221
 – functional dyad 221
 – sequence 218, 221
 – structure 221
 seal resistance 48
Segestria florentina 128, 131
 selective 2nd generation K_{ATP} modulating drugs 349 f.
 selectivity
 – hERG channel 301
 – Kv1.5 301
 sertindole 440
 severe myoclonic epilepsy of infancy 395
 ShK 215, 248
 – pharmacological properties 225
 – selectivity 220, 222
 – ShK-Dap 220, 222, 235
 – ShK-F6CA 220, 222
 – structure 221
 ShK(L5) 217, 220, 222, 225, 235 f., 246
 – plasma level 248
 – selectivity 222
 – toxicity 248
 sickle cell anemia 324
 similarity searches 298
 sinus node dysfunction 391
 site-directed mutagenesis 50, 302
 Sjögren's syndrome 238
 SK_{Ca} 327
 Slo 312
 slow channel syndrome 409
 small molecules inhibitors 222
 small-conductance 310
 smooth muscle K_{ATP} 335
 snake toxins
 – α -dendrotoxin 220
 – disulfide pattern 220
 SNX-482 68
 sodium channel expression 157
 – central nervous system 157
 – peripheral nervous system 157
 – subcellular expression 158
 sodium channels 7, 28, 31, 151, 382, 397
 spinal nerve ligation (SNL)
 (Chung) model 361 ff.
 spinocerebellar ataxia 76
 – type 6 401
 S4 regions 30 f.

- S4 segment 30
- SS9947 289
- SSR149744C 278
- stargazer 77
- state-dependent 56, 112
 - block 44, 112
 - inhibition 20, 112
- states 37 ff., 46 ff., 53, 112
 - closed 37, 44 ff., 55, 112
 - inactivated 37, 44, 46, 55, 112
 - open 37, 44 f., 55, 112
- steroids 230
- Stichodactyla helianthus* toxin (ShK)
 - ShK(L5) 217
 - ShK-Dap²² 217
 - ShK-F6CA 217
- streptozotocin model 369
- stroke 243, 322
- structure-based model 428
- subdural hematoma 325
- substituted L-amino acids 132 ff.
- sulfimidebenzamidoindanes 228
- sulfonylurea-receptor 208, 385
- super-smeller 244
- SUR1/Kir6.2 openers 340
- SUR2B splice variants 344
- SUR2B/Kir6.2 openers 343
- surface plasmon resonance 429
- synprint 75
- syntaxin 1 75
- systemic lupus erythematosus 238

- t**
- tactile allodynia 359 ff.
- tail current 44
- T cell 215, 231 ff.
 - ³H-thymidine incorporation 225
 - activation 234
 - calcium signaling 235
 - human 231 ff.
 - IL2 production 225
 - membrane potential 235
 - memory 232, 250
 - minipig 231 ff.
 - mouse 231 ff.
 - naïve 231 ff., 250
 - proliferation 225, 233
 - rat 231 ff.
 - T_{CM} 236 ff.
 - T_{EM} 236 ff.
- tlymphocyte 231 ff.
- T_{CM} 236 ff., 247 ff.
- T1DM 247
- T_{EM} 236 ff., 247, 247 ff.
- terfenadine 430, 434
- tetraethylammonium 207, 222
- tetraphenylporphyrins 228
 - structure 223
- tetrodotoxin (TTX) 42, 168
 - *in vivo* evaluation 178 ff.
 - structure 178 ff.
- TH-1177 91 ff.
- thermal hyperalgesia 359
- Thomsen's disease 403
- thorough QT/QTc study 448
- three-dimensional QSAR 434
- torsade de pointes 449
- toxins 86
- TRAM-34 232, 236, 240, 248, 315
- TRAM-39 324
- transient receptor potential channels 392
- transmural dispersion of repolarization 458
- transplant rejection
 - pathogenesis 250
 - therapies 250
- triphenylmethyl 324
- triterpene 324
- TRPM6 392
- TTX
 - analgesia 180 ff.
 - binding site 169 ff.
 - blocking properties 169 ff.
 - *in vivo* efficacy 179 ff.
 - neurodegenerative disease states 186
 - selectivity 169 ff.
- two-electrode voltage clamp 50
- two-pore K⁺ channels 197, 200 ff.
- ³H-thymidine incorporation 225
- T-type 66
- T-type Ca²⁺ channels 42, 84
 - CACNA1G 84
 - CACNA1H 84
 - CACNA1I 84
 - Cav 3.1 (or α 1G) 84
 - Cav 3.3 (α 1I) 84
 - characteristics 85
 - hypertension 92
 - kidney function 93
 - knockout mice 93
 - methodology 85
 - nociception 94
 - pharmacology 86
 - splice variants 85
 - thalamic dysrhythmias 94
- T-type channels 403
- type-1 diabetes mellitus (T1DM) 215, 237

- GAD65 249
- insulin 249
- pathogenesis 249
- tyrosine kinase 235

u

- U-92032 91 ff.
- UCL-1606 324
- UCL-1608 324
- UCL-1684 328
- UK-78282
 - Hill coefficient 226
 - pharmacological properties 225
 - selectivity 226
- UK78282 235
 - selectivity 220
 - structure 223
- urinary incontinence 316
- use dependence 28, 45
 - inhibition 20

v

- V = IR 53
- $V_{0.5, \text{inact}}$ 47
- valproic acid 87 ff.
- vascular smooth muscle 55
- ventricular arrhythmia 339
- verapamil 90, 278
 - stereoselectivity 105
 - structure 223
- veratridine 55
- VGCC modulation 72
- vinpocetine 174
 - structure 175
- vitamin D 115
- volatile anaesthetics 139
- volsurf 431
- voltage-dependent

- block 27, 54
- inhibition 20
- voltage-gated calcium channels (VGCC)
 - high voltage activated (HVA) 84
 - low voltage activated (LVA) 84
 - subunit 85
- voltage-gated K^+ channels 194, 199 ff.
- voltage-gated sodium channels 151, 393
 - action potential generation 151
 - blockers 168
 - drugs 168
 - impulse propagation 151
 - membrane proteins 151
- voltage-sensing
 - S4 segments 14
 - dyes 43

w

- waggler 77
- WAY-133537 344
- WIN 17317-3 319
- WIN-17317-3 224
 - pharmacological properties 225
 - structure 223

x

- XE-991 358 ff., 359
- xenopus oocytes 39, 50

y

- Y5-receptor antagonist 437

z

- ZD0947 343
- ZD6169 343 f.
- ZM244085 344 f., 347
- Zn^{2+} 86
- zonisamide 87 ff.

